Given that these drugs were capable of inducing CD83 expression in MCL, and our data showed the synergistic effect of anti‐CD83 ADC with a conventional chemotherapy (DOX and CP), these patients may benefit from combination regimens of chemotherapy and anti‐CD83 ADC. The gene discussed is CD83; the disease is mantle cell lymphoma.